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(TNFa)Abstract Aim of the work: To evaluate the clinical signiﬁcance of serum levels of tumor necrosis
factor alpha (TNFa) and -308 G/A promoter polymorphism in rheumatoid arthritis (RA) patients.
Patients and methods: We studied 43 RA patients and 30 controls. Demographic, clinical and
serological data were prospectively evaluated. Disease activity score (DAS28) and the Health
Assessment Questionnaire (HAQ) were assessed. Serum TNF-a level was measured and promoter
(-308 G/A) genotyped.
Results: Serum TNF-a level was signiﬁcantly higher in the RA patients compared to controls
(p= 0.036) and was signiﬁcantly higher in those with AA promoter polymorphism who had a sig-
niﬁcantly younger age at disease onset. In the multivariate analysis, disease duration would predict
the TNFa level (p= 0.006) while age at disease onset, DAS28 and HAQ would predict the TNFa
polymorphism (p= 0.004, p= 0.04 and p= 0.03 respectively). A signiﬁcant negative correlation
was present between TNFa level with age (p= 0.001) and age at disease onset (p< 0.0001) while
in those with GA genotype a signiﬁcant negative correlation was present with DAS28 (r= 0.66,
p= 0.038).
Conclusion: Serum TNFa levels and -308 G/A promoter polymorphism were higher in RA
patients than in controls and could be predicted by disease activity and HAQ.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Cytokine unbalance is responsible for the pathogenesis of
diverse inﬂammatory, autoimmune and infectious diseases
[1]. Rheumatoid arthritis (RA) is a model of multigenicinﬂammatory disorder in which tumor necrosis factor-alpha
(TNF-a) plays an important and central role in its etiology
and pathogenesis [2,3]. Overproduction of TNF-a is thought
to be the main contributor to increased ROS release in RA
patients, leading to tissue damage associated with the inﬂam-
mation [4]. Genetic factors may be implicated in the suscepti-
bility to disease initiation and in the severity of its course
[2,3]. TNF-a and gene expression are the key regulators of
inﬂammation and critical for RA [5]. It is substantiated that
RA is favored by the presence of the -308 TNF promoter
50 T.A. Gheita et al.polymorphism which is responsible for the increased TNF pro-
duction [2]. There are, however, controversial reports that
TNF-a promoter -308 A/G polymorphism may be an indepen-
dent marker of RA susceptibility and severity [6–8].
The TNF gene is located on chromosome six within the
major histocompatibility complex (MHC). Mutation affects
the -308 promoter region of the TNF gene which deﬁnes the
TNF1 and TNF2 alleles, determining low and high levels of
TNF expression, respectively [1,2]. The TNF-a -308 polymor-
phism in the promoter region with the TNF2 allele was found
in almost a quarter of RA patients and 10% of normal subjects
[9]. It has been linked to increased susceptibility and severity in
a variety of autoimmune and inﬂammatory disorders, includ-
ing RA, systemic lupus erythematosus (SLE) and inﬂamma-
tory bowel disease. Signiﬁcant impact of -308 promoter
polymorphism is the increased TNF production and this dif-
ference does not appear to be due to other genes lying within
the MHC region [1,2,9]. Moreover, there is a great deal of evi-
dence that points to the association of the TNF-a and/or its
gene -308 G/A promoter polymorphism with pathogenesis
and involvement in the disease susceptibility and severity of
SLE [9,10] and JRA [11–13].
Polymorphisms affecting the TNFa gene and its regulatory
regions are associated with RA prevalence and course. There is
a possible association between these polymorphisms and the
clinical response to the use of anti-TNFa antibodies. The pos-
sibility that the determination of genotype -308 may have
prognostic and therapeutic consequences was argued [14].
The introduction of anti-TNF agents has improved the out-
come for many patients with RA and the only replicated
genetic predictor of anti-TNF response is the -308 G/A sin-
gle-nucleotide polymorphism in the TNF promoter region.
The presence of -308 TNF G/G genotype appears to be a mar-
ker of good response to anti-TNF treatment [15]. Meanwhile,
a meta-analysis showed that the TNF-a -308 A/G polymor-
phism is not associated with responsiveness to TNF blockers
in RA patients [16].
The aim of the present study was to evaluate the clinical
signiﬁcance of serum levels of tumor necrosis factor alpha
(TNFa) and -308 G/A promoter polymorphism in rheumatoid
arthritis (RA) patients and ﬁnd any association with age at
disease onset, clinical and laboratory features and disease
activity.
2. Patients and methods
Forty-three rheumatoid arthritis patients with deﬁnite RA
diagnosed according to the 2010 ACR/EULAR RA classiﬁca-
tion criteria [17] were consecutively recruited from the Rheu-
matology outpatient clinic and the department of Cairo
University Hospitals. Full history taking, thorough clinical
examination, laboratory and plain X-ray investigations of
the affected joints were performed for all the patients. All
patients were regularly receiving methotrexate with or without
corticosteroids or chloroquine. Disease activity score in 28
joints (DAS-28) was calculated [18]. The Health Assessment
Questionnaire-II (HAQ-II) was used [19]. Radiological grad-
ing of the hands and feet of the studied RA patients was
assessed and percentage damage was calculated according to
the modiﬁed Larsen score [20]. The study was approved by
the local university ethics committee and the study conformsto the provisions of the Declaration of Helsinki in 1995. All
patients gave their informed consent prior to their inclusion
in the study.
Serum TNF-alpha was assayed using a Human TNF-alpha
ELISA kit (quantitative sandwich enzyme immunoassay tech-
nique), provided by Ray Biotech, Inc.2.1. Determination of TNF-a gene (-308) promoter region
polymorphism
Promoter region polymorphism of TNF-alpha gene (-308 G/A)
was determined by the polymerase chain reaction-restriction
fragment polymorphism (PCR-RFLP) technique.2.2. DNA isolation and TNF-alpha genotyping
Genomic DNA was isolated from white blood cells (WBCs) of
peripheral blood using a Biospin Whole Blood Genomic DNA
Extraction Kit (Bioﬂux Corporation, Arrow Plaza, Tokyo,
Japan). Enzymatic ampliﬁcation was performed by a PCR
using the Master Taq polymerase enzyme and Hybaid thermal
cycler (Promega Corporation, 2800 Woods Hollow Road
Madison, W 153711-5399 USA). Ampliﬁcation of the pro-
moter region (-308 G/A) of the TNF-alpha gene was per-
formed as proposed by Dalziel et al. [21] using 2 primers
which were purchased from Operon Biotechnologies (GmbH/
Biocampus, Germany).
Forward: Primer 50-AGGCAATAGGTTTTGAGGGCCA
T-30, and Reverse Primer: 50-ACACTCCCCATCCTCCCTG
CT-30. The PCR reaction mixture (25 ll) contained 12.5 ll
2· PCR Master Mix {10· PCR buffer, 4 mM MgCl2, 0.5
Taq DNA polymerase/ll, and 0.4 mM dNTPs (dATP, dCTP,
dGTP, dTTP)}, 1 ll of each primer (25 pmol), 3 ll of genomic
DNA and 7.5 ll sterilized nuclease-free water. The reaction
was carried out with the following cycles: 95 C for 2 min; 35
cycles of 95 C for 30 s, 60 C for 15 s and 74 C for 15 s;
and 74 C for 10 min for ﬁnal extension. Then ampliﬁed prod-
ucts were digested with 5 units Fast Digest NcoI restriction
enzyme at 37 C for 10 min (supplied by Fermentas, LT-
02241 Vilnius, Lithuania).The digested products were then
detected in 3.5% agarose gel containing ethidium bromide
by performing E/P on the gel electrophoresis apparatus and
visualized by UV transillumination (Promega, USA) for the
identiﬁcation of TNF-alpha gene (-308 G/A) promoter poly-
morphism. A single band at 107 bp identiﬁed AA homozygous
individuals, two bands at 87 and 20 bp identiﬁed GG homozy-
gous individuals, and three bands at 107, 87 and 20 bp indi-
cated a heterozygote at the TNF-a -308 locus, while the
20 bp band was very small to be viewed on the gel.
Statistical analysis: Data were collected, tabulated and ana-
lyzed by SPSS package version 15 (SPSS corporation, USA).
Data were summarized as mean ± SD. Mann–Whitney test
was used for the comparative analysis of 2 quantitative data.
Non-parametric analysis of variance (Kruskal–Wallis) was
used for the comparison of more than two groups; Spearman’s
correlation analysis was used for the detection of the relation
between 2 variables. Logistic regression analysis was applied
to detect the predictors for the elevated TNF-a level and pro-
moter polymorphism. Results were considered signiﬁcant at
p< 0.05.
Figure 1 Box plot of the serum TNF-a levels in the RA patients
and controls according to the TNFa (-308 G/A) promoter
polymorphism type.
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There were 43 RA patients (40 females and 3 males) and 30 age
and sex matched healthy controls with a mean age of
43.53 ± 3.23 years and were all females with 2 males. The mean
TNFa level for controls (5.57 ± 3.84 pg/ml) was signiﬁcantly
lower than the level in patients (p= 0.036). The demographic,
clinical and laboratory features of and medications used by the
RA patients are presented in Table 1. All the patients were
irregularly receiving diclofenac sodium (50–100 mg) while only
three were receiving full dose of sulfasalazine (2000 mg/day).
Three of the patients were diabetic and hypertensive with two
of them having HCV which was also present in another two
patients. Anti-cyclic citrullinated peptide (Anti-CCP) was posi-
tive in 74.42% of the patients. None of the patients gave family
history for any rheumatic disease. There were 62.8% with GG
TNFa (-308 G/A) gene promoter polymorphism, 23.2% with
GA and 14% with AA while it was GG in all the controls.
The TNFa was signiﬁcantly higher in patients with AA (480 ±
621.6 pg/ml) compared to those with GG (9.98 ± 23.63 pg/ml)
and GA (92.81 ± 48.58 pg/ml), (p= 0.000) (Fig. 1). Further-
more, there was a signiﬁcant difference in age at disease onset
according to the three gene promoters (p= 0.007) being older
in those with GG (37.06 ± 15.21 years) compared to those with
GA (24.7 ± 11.2 years) and AA (19.33 ± 11.93 years). There
were no other signiﬁcant differences in the characteristic fea-
tures of the patients according to the promoter genes.
A signiﬁcant negative correlation was present between the
TNFa level with age of the patients (r=0.49, p=0.001) and
age at disease onset (r= 0.58, p< 0.0001). On using multiple
linear regression analysis including age, age at disease onset
and disease duration, only the disease duration would predict
the TNFa level (p= 0.006) while age at disease onset would
highly predict the TNFa (-308 G/A) promoter polymorphismTable 1 Demographic, clinical and laboratory features of the
rheumatoid arthritis patients.
Feature RA patients (n= 43)
Mean ± SD
Age (years) 40.9 ± 15.5
Disease duration (years) 9.2 ± 7.2
Morning stiﬀness (min) 25.4 ± 37.6
No. of swollen joints 2.1 ± 3.3
No. of tender joints 6.8 ± 8.1
VAS (mm) 36.2 ± 34
ESR (mm/1st h) 53.2 ± 24.04
Hemoglobin (g/dl) 11.2 ± 1.7
Platelets (·103/ml) 305.9 ± 90.2
TNFa (pg/ml) 94.8 ± 269.6
Modiﬁed Larsen score 38.5 ± 16
DAS28 4.6 ± 1.7
HAQ 0.8 ± 0.8
Medications:
Methotrexate (35/43) 15.4 ± 8.4
Prednisolone (19/43) 3.8 ± 6.7
Leﬂunomide (9/43) 4 ± 7.9
Chloroquine (22/43) 125 ± 133.6
VAS, visual analog scale; ESR, erythrocyte sedimentation rate;
TNFa, tumor necrosis factor alpha; DAS28, disease activity score
in 28 joints; HAQ, health assessment questionnaire.(p= 0.004). DAS28, HAQ or steroid dose could not predict
the serum TNFa level while both DAS28 and HAQ would pre-
dict the TNFa (-308 G/A) promoter polymorphism (p= 0.04
and 0.03 respectively). No signiﬁcant correlation was present
with the other clinical and laboratory features or disease activ-
ity. However, in those patients with GA genotype of TNFa
polymorphism there was a signiﬁcant negative correlation of
the serum TNF-a level with the DAS28 (r= 0.66, p= 0.038)
(Fig. 2) which was only a tendency in those with AA genotype
(r= 0.81, p= 0.05). There was a tendency for an association
between the TNFa level and the modiﬁed Larsen score in the
RA patients with GG genotype (r= 0.48, p= 0.058). There
was a tendency for a higher TNFa in the four patients with
HCV (463.03 ± 833.5 pg/ml) compared to those without
(57.06 ± 98.7 pg/ml).Figure 2 Correlation of the serum TNFa level and DAS28 in
RA patients with GA -308 promoter polymorphism.
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In the present study, there was a signiﬁcant elevation in the
serum TNF-a levels in the RA patients and this was associated
with the increased polymorphisms in its gene promoter region.
None of the controls in the present study had any promoter
polymorphism. This is in agreement with the results of another
study that found elevated TNF-a in the plasma and synovial
ﬂuid from RA patients and was associated with polymor-
phisms in the promoter region of the TNF-a gene. However,
in disagreement to our results was their results that found no
differences in genotype distribution and allelic frequencies of
-308 G/A TNF-a promoter polymorphism between RA
patients and controls [3,6]. Interindividual variation in the
expression of TNF suggests the existence of functionally dis-
tinct TNF alleles including -308 promoter polymorphism that
could play a role in RA susceptibility [22].
All the RA patients in the present study were Egyptian and
the TNFa -308 A/G promoter polymorphism was considered
as an obvious risk factor compared to the controls especially
those with juvenile onset. None of the controls had the A allele
and all had the G allele. In the present RA patients, the A
allele was heterozygous in 23.26% and homozygous in
13.95%. It may be thus thought of the G allele as a protective
from the development of RA in Egyptians. In a meta-analysis
study, TNF-a -308 A/G polymorphism represented a signiﬁ-
cant risk factor for RA in Latin Americans, but not in Euro-
peans which favors that different ethnic populations
inﬂuence this association [7]. The -308 G/A polymorphism
was signiﬁcantly associated with a poor outcome in the Turk-
ish juvenile idiopathic arthritis (JIA) patients (p= 0.005) but
there was no association in the Czech patients. This genetic
variation may accompany the phenotypic differences found
[23]. Again, analysis of the TNFa -308 AA allele showed
increased frequency in severe RA when compared to non-
severe disease and to healthy controls. This association might
be used as a prognostic marker for severe RA [24]. Contrarily,
TNF -308A itself or a neighboring gene may be a protective
factor for the development of RA in some of the population
in Taiwan [25]. In another study, polymorphism TNF -308A
was less prevalent among RA patients (1.7%) than controls
and found that the A allele at -308 locus provides protection
against RA in North Indians [26]. Again, another study found
that the distribution of TNF-genotypes in RA patients did not
differ from that in controls, suggesting that TNF-a -308 pro-
moter polymorphism is not a genetic risk factor for RA sus-
ceptibility and severity [6,8,27]. A meta-analysis study
showed that the TNF-a -308 A/G polymorphism may repre-
sent a signiﬁcant risk factor for RA in Latin Americans but
not in the European, Arab, or Asian populations [28].
Considering the relevance of TNF-a in the pathophysiology
of JIA, it is likely that polymorphisms in its promoter area
may be relevant in disease susceptibility and activity.
Twenty-four percent of JIA Portuguese patients presented
the -308 GA/AA genotypes and 76% the GG, similar to ﬁnd-
ings in controls thus conferring no association with disease
susceptibility [29]. However, the -308 G/A polymorphism
tends to be more frequent in the systemic onset rather than
the oligoarticular JIA patients [30].
In the present study, there was no association of the
TNF-a -308 promoter with the other clinical or laboratorymanifestations of the RA patients. In agreement, the TNF pro-
moter polymorphisms at position -308, were not related to the
clinical manifestations of RA patients [25]. Moreover, there
was also no correlation between TNF-a polymorphism and
disease activity measures, including ESR, CRP, number of
swollen and tender joints, and morning stiffness duration [6].
In the present study, a signiﬁcant negative correlation was
present between the TNFa level with age of the patients
(r= 0.49, p= 0.001) and age at disease onset (r= 0.58,
p< 0.0001). On using multiple linear regression analysis
including age, age at disease onset and disease duration, only
the disease duration would predict the TNFa level
(p= 0.006) while age at disease onset would highly predict
the TNFa (-308 G/A) promoter polymorphism (p= 0.004).
There was no signiﬁcant association of TNFa promoter varia-
tion at positions -308 and -238 with susceptibility to RA. How-
ever, a signiﬁcant difference in the mean age at disease onset
was found between -238 TNFa genotypes. In addition, a dif-
ference in the presence of nodular disease was observed
between -308 TNFa genotypes suggesting that TNF a gene
may play a role in the disease proﬁle of RA patients [31].
Others found no association between TNF-a genotypes, age
at disease onset, disease activity, and joint and extra-articular
involvement [6].
In the present study, both DAS28 and HAQ would predict
the TNFa (-308 G/A) promoter polymorphism. Patients with
GA genotype showed a signiﬁcant negative correlation of the
serum TNF-a level with the DAS28 (r=0.66, p=0.038) while
there was a tendency for this association in those with AA
genotype (r= 0.81, p= 0.05). TNF-a -308 GA/AA genotypes
were found to be related to higher inﬂammatory activity and
worse measures of disease activity in rheumatoid patients com-
pared to those with GG genotype [29]. TNF promoter gene
polymorphisms and TNF receptor gene heterogeneity play a
signiﬁcant role in non-response to biologic agents and disease
course/severity [32]. In a study on active Chilean RA patients
genotyped for -308 TNFa polymorphism who were treated by
an anti-TNF-a agent, 88.2% of G/G and 68.4% of G/A geno-
types were DAS28 responders and the serum TNFa levels of
the G/A patients were lower than those of the G/G patients.
A negative relationship occurred between DAS28 improve-
ment and increased circulating TNFa levels [33]. The mean
TNF-a level increased signiﬁcantly with respect to basal levels
in most of patients after anti-TNF-a therapy and was inversely
related to the improvement in disease activity [34]. In JIA
patients with the genotype -308 GG achieved an obvious
improvement in disease activity at month 6 more frequently
than those with the genotype -308 GA or AA [35]. Patients
not responding to anti-TNF therapy showed an increased fre-
quency of the A allele. The signiﬁcant association between the
TNF-a promoter -308 A/G polymorphism and responsiveness
to anti-TNF therapy, suggests that RA patients who carry the
A allele have a poorer response to therapy than those with the
G allele [36,37].
Patients with a TNFa -308 G/G genotype are better
responders to anti-TNFa treatment than those with A/A or
A/G genotypes irrespective of the treated rheumatic disease
(RA, psoriatic arthritis or ankylosing spondylitis) [38]. In a
previous study including another TNF gene -863A allele it
was suggested that it can be used as a genetic marker for
SLE susceptibility and was associated with high TNF-a
Clinical signiﬁcance of serum TNFa and -308 G/A promoter polymorphism 53production, Raynaud phenomenon, and nephritis in juvenile
SLE patients [39].
Almost three quarters of the patients in the present study
had positive anti-CCP. The TNF- 308A allele is less frequently
found in rheumatoid factor negative but not in rheumatoid
factor positive polyarthritis and may therefore be associated
with a more severe disease, while the more common TNF -
308G allele may be protective [12]. In this study, there was a
tendency for an association between the TNFa level and the
modiﬁed Larsen score in the RA patients with GG genotype.
Although the introduction of anti-TNF antibodies has con-
tributed to the slowing and arrest of RA progression, destruc-
tion itself has been generally acknowledged as an irreversible
process with little hope in resolution [40]. Another study
reported that erosive damage in patients with recent-onset
RA is not inﬂuenced by the -308 TNF-a genotype [41].
In conclusion, serum TNFa levels and -308 G/A promoter
polymorphism were higher in RA patients than in healthy con-
trols and could be predicted by the disease activity and HAQ.
Only the disease duration would predict the TNFa level while
age at disease onset, DAS28 and HAQ would predict the
TNFa (-308 G/A) promoter polymorphism. To conﬁrm our
results we propose that larger scale, multicentre studies with
longer evaluation periods are needed in selected RA patients
using direct sequencing of the genotype.
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